Nexalin Technology (NXL) Shares Outstanding (Diluted Average) (2022 - 2026)
Nexalin Technology (NXL) recorded quarterly Shares Outstanding (Diluted Average) of $19.8 million in Q1 2026, up 20.91% quarter-over-quarter from $16.4 million in Q4 2025, and up 48.95% on a YoY basis from $13.3 million in Q1 2025.
Nexalin Technology (NXL) Shares Outstanding (Diluted Average) (2022 - 2026) Analysis & Trends
Nexalin Technology's Shares Outstanding (Diluted Average) history runs 5 years deep, the most recent figure standing at $19.8 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Diluted Average) rose 48.95% year-over-year to $19.8 million; the TTM figure through Mar 2026 stood at $19.8 million (up 48.95% YoY), while the FY2025 annual figure was $16.4 million, up 77.87% from the prior year.
- Shares Outstanding (Diluted Average) was $19.8 million for Q1 2026 at Nexalin Technology, up from $16.4 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $19.8 million in Q1 2026 to a low of $4.9 million in Q2 2022.
- Historically, Shares Outstanding (Diluted Average) has averaged $9.8 million across 5 years, with a median of $7.5 million in 2024.
- The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Diluted Average) gained 2.06% in 2024, then soared 93.75% in 2025.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $5.6 million in 2022, then soared by 32.03% to $7.4 million in 2023, then gained by 25.26% to $9.2 million in 2024, then jumped by 77.87% to $16.4 million in 2025, then grew by 20.91% to $19.8 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $19.8 million (Q1 2026), $16.4 million (Q4 2025), and $15.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 1.75 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 386.50 Mn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 1.29 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 1.50 Bn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 580.70 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 393.60 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 457.00 Mn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | - |
| 10 | Nexalin Technology | 7.82 Mn | 5.11 Mn | 13,133.00 | 19.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.82 Mn |
| Dec 31, 2025 | 16.39 Mn |
| Sep 30, 2025 | 15.63 Mn |
| Jun 30, 2025 | 14.53 Mn |
| Mar 31, 2025 | 13.31 Mn |
| Dec 31, 2024 | 9.22 Mn |
| Sep 30, 2024 | 8.61 Mn |
| Jun 30, 2024 | 7.50 Mn |
| Mar 31, 2024 | 7.44 Mn |
| Dec 31, 2023 | 7.36 Mn |
| Sep 30, 2023 | 7.42 Mn |
| Jun 30, 2023 | 7.29 Mn |
| Mar 31, 2023 | 7.29 Mn |
| Dec 31, 2022 | 5.57 Mn |
| Sep 30, 2022 | 5.19 Mn |
| Jun 30, 2022 | 4.90 Mn |